前收市價 | 14.50 |
開市 | 14.50 |
買盤 | 14.30 |
賣出價 | 15.05 |
拍板 | 125.00 |
到期日 | 2025-06-20 |
今日波幅 | 14.50 - 14.50 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 277 |
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.